|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 31, 2018 ) Singapore,
A global report titled Hepatocellular Carcinoma Drugs Market has been introduced into our library of 2.5 million reports.
About the market report:
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease. Analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.
To access the full table of contents of the report click below: https://www.marketintelreports.com/report/tech0756/global-hepatocellular-carcinoma-drugs-market-20172021
Covered in this report
The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer
• Eli Lilly
• Johnson and Johnson
• Pfizer
Other prominent vendors
• Bristol-Myers Squibb
• Celgene
• F. Hoffmann-la Roche
• Gilead
• GlaxoSmithKline
• Merck
• Novartis
• Salix Pharmaceuticals
• Transgene
There are 14 Chapters to deeply display the global Hepatocellular Carcinoma Drugs market.
To find out more of the report or request some customization: https://www.marketintelreports.com/inquiry-before-buying.php?id=tech0756
Table of Contents-Key Points Covered
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
• Market size and forecast
• Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by therapy
• Chemotherapy
• Brachytherapy
• Ablation therapy
PART 08: Geographical segmentation
• HCC drugs market in Americas
• HCC drugs market in EMEA
• HCC drugs market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Increase in R&D activities for liver cirrhosis medication
• Rise in awareness
Continued…..
Complete Report Details @ https://www.marketintelreports.com/report/tech0756/global-hepatocellular-carcinoma-drugs-market-20172021
About us:
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 2.5 million titles and 200 publishers on our platform and are growing consistently to fill the “World Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
MarketIntelReports
Lakshmi
1-302-261-5343
sales@marketintelreports.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
